Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute myeloid leukemia (AML). In this educational program, these experts review the pivotal, practice-changing data regarding the use of menin inhibitors in treating AML and lead case-based panel discussions to dissect the clinical implications and best practices for using these new agents in the clinic today.
This educational activity is an archive of the live symposium held on February 27, 2026.
Target Audience
This educational activity is directed toward hematologist-oncologists, advanced practice providers, and nurses involved in the treatment/management of patients with acute myeloid leukemia (AML).
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Describe the mechanism of action of menin inhibitors as a therapeutic strategy for AML
- Evaluate the latest efficacy and safety data of menin inhibitors in the treatment of patients with KMT2A-rearranged and NPM1-mutated relapsed/refractory AML
- Individualize therapy for patients with KMT2A-rearranged and NPM1-mutated relapsed/refractory AML based on evidence-based guidelines
- Apply recommended strategies to mitigate and manage adverse events associated with menin inhibitors in patients with AML
Naval G. Daver, MD
Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Naval G. Daver, MD, has no relevant financial relationships with ineligible companies.
Amir Fathi, MD
Professor
of Medicine
Harvard
Medical School
Program
Director, Center for Leukemia
Massachusetts
General Hospital
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Autolus, Bristol Myers Squibb, Daiichi Sankyo, Genmab, Kura, Novartis, Pfizer, Prelude, Remix, Schrödinger, Servier, Syndax, Takeda, Thermo Fisher; Grant/Research Funding: AbbVie, Bristol Myers Squibb, Kura, Servier
Guillermo Garcia-Manero, MD
Professor
and Chair, ad interim
Department
of Leukemia
The
University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Funding: Research Support: AbbVie, Ascentage, AstraZeneca, Bristol Myers Squibb, Chordia, Curis, Genentech, GSK, Novartis, Rigel, Servier, Taiho, Takeda, Zentalis
Aditi Shastri, MD
Attending
Physician, Department of Oncology, Division of Hematological Malignancies,
Cellular Therapy, and Bone Marrow Transplant
Associate
Professor of Oncology, Medicine, and Developmental & Molecular Biology
Director,
Clonal Hematopoiesis & Myelodysplastic Syndromes Clinics
Associate
Director, Translational Research, Blood Cancer Institute
Montefiore
Einstein Comprehensive Cancer Center
Bronx, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Geron,
Kymera Therapeutics, Ryvu Therapeutics; Grant/Research Funding:
Kymera Therapeutics, Ryvu Therapeutics; Other: Data Safety Monitoring
Board Chair for Servier Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.